Durchführung und Befundung der ¹²³I-mIBG-Szintigraphie bei Kindern und Jugendlichen mit Neuroblastom (Version 3) – DGN-Handlungsempfehlung (S1-Leitlinie), Stand: 2/2020 – AWMF-Registernummer: 031-040

Zusammenfasssung

Die aktualisierte 3. Fassung der ¹²³I-mIBG-Szintigrafie bei Kindern und Jugendlichen berücksichtigt folgende aktuelle Entwicklungen: Die Leitlinie fokussiert auf die diagnostische Anwendung von ¹²³I-mIBG beim Neuroblastom. ¹³¹I-mIBG kommt bei der Radionuklidtherapie zum Einsatz. An wenigen Stellen wird auf Besonderheiten des ¹³¹I-mIBG bei der Befundung von Posttherapie-Szintigrammen eingegangen. Es werden aktuelle Entwicklungen in der Patientenvorbereitung bei den Medikamenteninterferenzen und Empfehlungen zur Schilddrüsenblockade berücksichtigt. Neue Empfehlungen der zu applizierenden Aktivität werden genannt und die damit assoziierten Probleme diskutiert. Die Bildakquisition unter Berücksichtigung von SPECT bzw. SPECT/CT des Körperstammes inkl. des Kopfes wird berücksichtigt. Die Befundung unter Verwendung des SIOPEN-Scores wird neu aufgenommen. Auf PET bzw. PET/CT mit ¹⁸F-DOPA bzw. ⁶⁸Ga-DotaTATE wird verwiesen.

Schlüsselwörter

123I-mIBG-Szintigraphie - Neuroblastom - Kinder und Jugendliche - Diagnostik

Publication History

Received: 03 November 2021

Accepted: 18 February 2022

Article published online:
14 April 2022

• Literatur

• 1 Giammarile F, Boneu A, Edeline V. et al. Guide de realisation de la scintigraphie à la méta-iodobenzylguanidine (mIBG) en oncologie pédiatrique. Med Nucl 2000; 24: 35-41
• 2 Bar-Sever Z, Biassoni L, Shulkin B. et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging 2018; 45: 2009-2014
• 3 Simon T, Hero B, Schulte JH. et al. 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klin Padiatr 2017; 229: 147-167
• 4 Bombardieri E, Giammarile F, Aktolun C. et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010; 37: 2436-2446
• 5 Bonnin F, Lumbroso J, Tenenbaum F. et al. Refining interpretation of MIBG scans in children. J Nucl Med 1994; 35: 803-810
• 6 Decarolis B, Schneider C, Hero B. et al. 123I-mIBG scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol 2013; 31: 944-951
• 7 Decarolis B, Simon T, Krug B. et al. Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. BMC Cancer 2016; 16: 542
• 8 Gelfand M. Meta-iodobenzylguanidine in children. Semin Nucl Med 1993; 23: 231-242
• 9 Gelfand M, Elgazzar A, Kriss V. et al. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 1994; 35: 1753-1757
• 10 Giammarile F, Lumbroso J, Ricard M. et al. Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high-dose on tumour site detection. Eur J Nucl Med 1995; 22: 1180-1183
• 11 Jacobson AF, Deng H, Lombard J. et al. 123I-meta-iodobenzyl-guanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 2010; 95: 2596-2606
• 12 Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004; 45: 1172-1188
• 13 Kushner B, Cheung N. Exploiting the MIBG-avidity of neuroblastoma for staging and treatment. Pediatr Blood Cancer 2006; 47: 863-864
• 14 Lumbroso J, Guermazi F, Hartmann O. et al. Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res 1988; 271: 689-705
• 15 Parisi M, Greene M, Dykes T. et al. Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol 1992; 27: 768-773
• 16 Perel Y, Conway J, Kletzel M. et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21: 13-18
• 17 Sharp SE, Gelfand MJ, Shulkin BL. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med 2011; 41: 345-353
• 18 Wieland D, Wu J, Brown L. et al. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980; 21: 349-353
• 19 Cohn SL, Pearson ADJ, London WB. et al. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. J Clin Oncol 2009; 27: 289-297
• 20 Monclair T, Brodeur GM, Ambros PF. et al. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. J Clin Oncol 2009; 27: 298-303
• 21 Kaatsch P, Grabow D, Spix C. German Childhood Cancer Registry – Annual Report 2017 (1980–2016). Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University Mainz. 2018 http://www.kinderkrebsregister.de
• 22 Kinnier-Wilson L, Draper G. Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br Med J 1974; 3: 301-307
• 23 Schmidt M, Simon T, Hero B. et al. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 2008; 44: 1552-1558
• 24 Kushner B, Yeh S, Kramer K. et al. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003; 21: 1082-1086
• 25 Lumbroso J, Hartmann O, Schlumberger M. Therapeutic use of [131I]-metaiodo-benzylguanidine in neuroblastoma: a phase II study in 26 patients. “Societe Francaise d'Oncologie Pediatrique” and Nuclear Medicine Co-investigators. J Nucl Biol Med 1991; 35: 220-223
• 26 Hoefnagel C, De Kraker J, Valdes Olmos R. et al. 131I. Q J Nucl Med 1995; 39 (Suppl. 01) 61-64
• 27 Schmidt M, Baum RP, Simon T. et al. Therapeutic nuclear medicine in pediatric malignancy. Q J Nucl Med Mol Imaging 2010; 54: 411-428
• 28 Schmidt M, Simon T, Hero B. et al. Is there a benefit of I-131-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006; 45: 145-151
• 29 Gordon I, Peters A, Gutman A. et al. Skeletal assessment in neuroblastoma – the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990; 31: 129-134
• 30 Friedmann NC, Hassan A, Grady E. Efficacy of thyroid blockade on thyroid radioiodine uptake in 123I-mIBG imaging. J Nucl Med 2014; 55: 211-215
• 31 GE Healthcare. Fachinformation für AdreView. http://www3.gehealthcare.de/~/media/downloads/de/fachinformationen %20constanze/jb41346de-adreview.pdf (deutsche Fassung), https://www.gehealthcare.com/-/media/a846f6c63dbe40b6932b089aaded56a4.pdf (englische Fassung).
• 32 Giammarile F, Chiti A, Lassmann M. et al. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 2008; 35: 1039-1047
• 33 Giubbini R, Milan E, Marcassa C. et al. 123I-mIBG thyroid uptake: implications for mIBG imaging of the heart. J Nucl Cardiol 2016; 23: 1335-1339
• 34 Stabin M, Gelfand M. Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med 1998; 42: 93-112
• 35 Knickmeier M, Schäfers M, Schober O. Two years´experience using no-carrier-added meta-[I-123]iodobenzylguanidine in clincal studies. Eur J Nucl Med 2001; 28: 941
• 36 Bundesamt für Strahlenschutz. Bekanntmachung der aktualisierten diagnostischen Referenzwerte für nuklearmedizinische Untersuchungen. BAnz AT 19.10.2012.
• 37 Jacobs F, Thierens H, Piepsz A. et al. Optimized tracer-dependent dosage cards to obtain weightindependent effective doses. Eur J Nucl Med Mol Imaging 2005; 32: 581-588
• 38 Lassmann M, Biassoni L, Monieurs M. et al. The New EANM Dosage Card. Eur J Nucl Med Mol Imaging 2007; 34: 796-798
• 39 Lassmann M, Biassoni L, Monsieurs M. et al. EANM Dosimetry and Paediatrics Committees. The new EANM paediatric dosage card: additional notes with respect to F-18. Erratum in: Eur J Nucl Med Mol Imaging 2008; 35: 2141. Eur J Nucl Med Mol Imaging 2008; 35: 1666-1668
• 40 Lassmann M, Treves ST. Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines. Eur J Nucl Med Mol Imaging 2014; 41: 1036-1041
• 41 Piepsz A, Hahn K, Roca I. et al. A radiopharmaceutical schedule for image in pediatric. Recommendations of the pediatric task group of the European Association of Nuclear Medicine. Eur J Nucl Med 1990; 17: 127-129
• 42 EANM Dosage Card. https://www.eanm.org/content-eanm/uploads/2017/01/EANM_Dosage_Card_040214.pdf
• 43 Ladenstein R, Lambert B, Pötschger U. et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging 2018; 45: 292-305
• 44 Mairs R. Neuroblastoma therapy using radiolabelled [131I]meta-iodobenzylguanidine ([131I]MIBG) in combination with other agents. Eur J Cancer 1999; 35: 1171-1173
• 45 Mairs RJ, Cunningham SH, Russell J. et al. No-carrier-added Iodine-131-MIBG: Evaluation of a therapeutic preparation. J Nucl Med 1995; 36: 1088-1095
• 46 Owens J, Bolster AA, Prosser JE. et al. No-carrier-added I-123-MIBG: an initial clinical study in patients with phaeochromocytoma. Nucl Med Commun 2000; 21: 437-440
• 47 Strahlenschutzkommission. Diagnostische Referenzwerte in der Nuklearmedizin. Empfehlungen der Strahlenschutzkommission – Verabschiedet in der 167. Sitzung der Strahlenschutzkommission am 6./7. Juli 2000.
• 48 Pintelon H, Jonckheer M, Piepsz A. Paediatric nuclear medicine procedures: routine sedation or management of anxiety. Nucl Med Commun 1994; 15: 664-666
• 49 Rogasch JMM, Amthauer H, Furth C. et al. I-123-MIBG scintigraphy in patients with neuroblastoma. Nuklearmedizin 2018; 57: 35-39
• 50 Brisse HJ, McCarville MB, Granata C. et al. International Neuroblastoma Risk Group Project. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011; 261: 243-257
• 51 Nakajo M, Shapiro B, Copp J. et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodo-benzyl-guanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983; 24: 672-682
• 52 Jacobsson H, Johansson L, Kimiaei S. et al. Concentration of 123I-metaiodobenzylguanidine in left and right liver lobes. Findings indicate regional differences in function in the normal liver. Acta Radiol 1999; 40: 224-228
• 53 Gelfand M. I-123-MIBG uptake in the neck and shoulders of a neuroblastoma patient: damage to sympathetic innervation blocks uptake in brown adipose tissue. Pediatr Radiol 2004; 34: 577-579
• 54 Okuyama C, Ushijima Y, Kubota T. et al. I-123-Metaiodobenzylguanidine uptake in the nape of the neck of children: likly visualization of brown adipose tissue. J Nucl Med 2003; 44: 1421-1425
• 55 Hattner RS, Pounds TR, Matthay KK. Normal cerebellar MIBG localization. Implications in the interpretation of delayed scans. Clin Nucl Med 1994; 19: 985-988
• 56 Kushner BH, Yeung HW, Larson SM. et al. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18-fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19: 3397-3405
• 57 Melzer HI, Coppenrath E, Schmid I. et al. ¹²³I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging 2011; 38: 1648-1658
• 58 Shulkin BL, Hutchinson RJ, Castle VP. et al. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996; 199: 743-750
• 59 Hoegerle S, Nitzsche E, Altehoefer C. et al. Pheochromocytomas: detection with F18-DOPA whole-body PET – initial results. Radiology 2002; 222: 507-512
• 60 Piccardo A, Lopci E, Conte M. et al. Comparison of (18)F-DOPA PET/CT and (123)I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging 2012; 39: 57-71
• 61 Shulkin BL, Wieland DM, Baro ME. et al. PET Hydroxyephedrine Imaging of Neuroblastoma. J Nucl Med 1996; 37: 16-21
• 62 Solanki K, Bomanji J, Moyes J. et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13: 513-521
• 63 Franzius C, Hermann K, Weckesser M. et al. Whole-body PET/CT with C-11-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with I-123-mIBG SPECT/CT. J Nucl Med 2006; 47: 1635-1642
• 64 Franzius C, Riemann B, Vormoor J. et al. Metastatic neuroblastoma demostrated by whole-body PET-CT using C-11-HED. Nuklearmedizin 2005; 44: N4-N5
• 65 Kroiss A, Putzer D, Uprimny C. et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 2011; 38: 865-873
• 66 Gains JE, Bomanji JB, Fersht NL. et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med 2011; 52: 1041-1047
• 67 Pfluger T, Schmied C, Porn U. et al. Integrated imaging using MRI and I-123-metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnodid of pediatric neuroblastoma. Am J Roentgenol 2003; 181: 1115-1124
• 68 Sisson J, Shulkin B. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999; 43: 217-223